Clotting activation after oral anticoagulant therapy discontinuation: A risk factor for recurrent venous thromboembolism

Daniela Poli, Emilia Antonucci, Emanuele Cecchi, Irene Betti, Ilaria Lapini, Alessandra Gazzini, Rosanna Abbate, Gian Franco Gensini, Domenico Prisco

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A hypercoagulable state has been reported in some patients treated for venous thromboembolism (VTE) after oral anticoagulant treatment (OAT) discontinuation. It is unclear whether this is a risk factor for thrombosis recurrence. We investigated 139 patients with VTE and followed them up for a median of 20.5 months (6-90 months) to evaluate whether fragment 1 + 2 (F1 + 2) plasma levels are prognostic for VTE recurrence and to confirm clotting activation after OAT withdrawal. Fourteen patients had recurrences during the follow-up. F1 + 2 was measured the day before OAT withdrawal (T0) and 4 weeks later (T1) and its levels were similar in patients with spontaneous VTE versus those with transient risk factors for VTE. F1 + 2 levels increased from T0 to T1 (P <0.0005). At T1, F1 + 2 values were significantly higher in patients with recurrence than in those without (P <0.005). The negative predictive value of normal levels of F1 + 2 at T1 was 95%. In carriers of thrombophilic conditions no correlation was found between F1 + 2 levels and VTE recurrence. The results of this study confirm clotting activation after OAT discontinuation and suggest that higher F1 + 2 plasma levels are an independent risk factor for VTE recurrence.

Original languageEnglish
Pages (from-to)221-225
Number of pages5
JournalBlood Coagulation and Fibrinolysis
Volume15
Issue number3
DOIs
Publication statusPublished - Apr 2004

Fingerprint

Venous Thromboembolism
Anticoagulants
Recurrence
Therapeutics
Reference Values
Thrombosis

Keywords

  • Clotting activation
  • Fragment 1 + 2
  • Oral anticoagulant withdrawal
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Clotting activation after oral anticoagulant therapy discontinuation : A risk factor for recurrent venous thromboembolism. / Poli, Daniela; Antonucci, Emilia; Cecchi, Emanuele; Betti, Irene; Lapini, Ilaria; Gazzini, Alessandra; Abbate, Rosanna; Gensini, Gian Franco; Prisco, Domenico.

In: Blood Coagulation and Fibrinolysis, Vol. 15, No. 3, 04.2004, p. 221-225.

Research output: Contribution to journalArticle

Poli, D, Antonucci, E, Cecchi, E, Betti, I, Lapini, I, Gazzini, A, Abbate, R, Gensini, GF & Prisco, D 2004, 'Clotting activation after oral anticoagulant therapy discontinuation: A risk factor for recurrent venous thromboembolism', Blood Coagulation and Fibrinolysis, vol. 15, no. 3, pp. 221-225. https://doi.org/10.1097/00001721-200404000-00004
Poli, Daniela ; Antonucci, Emilia ; Cecchi, Emanuele ; Betti, Irene ; Lapini, Ilaria ; Gazzini, Alessandra ; Abbate, Rosanna ; Gensini, Gian Franco ; Prisco, Domenico. / Clotting activation after oral anticoagulant therapy discontinuation : A risk factor for recurrent venous thromboembolism. In: Blood Coagulation and Fibrinolysis. 2004 ; Vol. 15, No. 3. pp. 221-225.
@article{bfc7d7031c674f359b5609fbaa4df77c,
title = "Clotting activation after oral anticoagulant therapy discontinuation: A risk factor for recurrent venous thromboembolism",
abstract = "A hypercoagulable state has been reported in some patients treated for venous thromboembolism (VTE) after oral anticoagulant treatment (OAT) discontinuation. It is unclear whether this is a risk factor for thrombosis recurrence. We investigated 139 patients with VTE and followed them up for a median of 20.5 months (6-90 months) to evaluate whether fragment 1 + 2 (F1 + 2) plasma levels are prognostic for VTE recurrence and to confirm clotting activation after OAT withdrawal. Fourteen patients had recurrences during the follow-up. F1 + 2 was measured the day before OAT withdrawal (T0) and 4 weeks later (T1) and its levels were similar in patients with spontaneous VTE versus those with transient risk factors for VTE. F1 + 2 levels increased from T0 to T1 (P <0.0005). At T1, F1 + 2 values were significantly higher in patients with recurrence than in those without (P <0.005). The negative predictive value of normal levels of F1 + 2 at T1 was 95{\%}. In carriers of thrombophilic conditions no correlation was found between F1 + 2 levels and VTE recurrence. The results of this study confirm clotting activation after OAT discontinuation and suggest that higher F1 + 2 plasma levels are an independent risk factor for VTE recurrence.",
keywords = "Clotting activation, Fragment 1 + 2, Oral anticoagulant withdrawal, Venous thromboembolism",
author = "Daniela Poli and Emilia Antonucci and Emanuele Cecchi and Irene Betti and Ilaria Lapini and Alessandra Gazzini and Rosanna Abbate and Gensini, {Gian Franco} and Domenico Prisco",
year = "2004",
month = "4",
doi = "10.1097/00001721-200404000-00004",
language = "English",
volume = "15",
pages = "221--225",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Clotting activation after oral anticoagulant therapy discontinuation

T2 - A risk factor for recurrent venous thromboembolism

AU - Poli, Daniela

AU - Antonucci, Emilia

AU - Cecchi, Emanuele

AU - Betti, Irene

AU - Lapini, Ilaria

AU - Gazzini, Alessandra

AU - Abbate, Rosanna

AU - Gensini, Gian Franco

AU - Prisco, Domenico

PY - 2004/4

Y1 - 2004/4

N2 - A hypercoagulable state has been reported in some patients treated for venous thromboembolism (VTE) after oral anticoagulant treatment (OAT) discontinuation. It is unclear whether this is a risk factor for thrombosis recurrence. We investigated 139 patients with VTE and followed them up for a median of 20.5 months (6-90 months) to evaluate whether fragment 1 + 2 (F1 + 2) plasma levels are prognostic for VTE recurrence and to confirm clotting activation after OAT withdrawal. Fourteen patients had recurrences during the follow-up. F1 + 2 was measured the day before OAT withdrawal (T0) and 4 weeks later (T1) and its levels were similar in patients with spontaneous VTE versus those with transient risk factors for VTE. F1 + 2 levels increased from T0 to T1 (P <0.0005). At T1, F1 + 2 values were significantly higher in patients with recurrence than in those without (P <0.005). The negative predictive value of normal levels of F1 + 2 at T1 was 95%. In carriers of thrombophilic conditions no correlation was found between F1 + 2 levels and VTE recurrence. The results of this study confirm clotting activation after OAT discontinuation and suggest that higher F1 + 2 plasma levels are an independent risk factor for VTE recurrence.

AB - A hypercoagulable state has been reported in some patients treated for venous thromboembolism (VTE) after oral anticoagulant treatment (OAT) discontinuation. It is unclear whether this is a risk factor for thrombosis recurrence. We investigated 139 patients with VTE and followed them up for a median of 20.5 months (6-90 months) to evaluate whether fragment 1 + 2 (F1 + 2) plasma levels are prognostic for VTE recurrence and to confirm clotting activation after OAT withdrawal. Fourteen patients had recurrences during the follow-up. F1 + 2 was measured the day before OAT withdrawal (T0) and 4 weeks later (T1) and its levels were similar in patients with spontaneous VTE versus those with transient risk factors for VTE. F1 + 2 levels increased from T0 to T1 (P <0.0005). At T1, F1 + 2 values were significantly higher in patients with recurrence than in those without (P <0.005). The negative predictive value of normal levels of F1 + 2 at T1 was 95%. In carriers of thrombophilic conditions no correlation was found between F1 + 2 levels and VTE recurrence. The results of this study confirm clotting activation after OAT discontinuation and suggest that higher F1 + 2 plasma levels are an independent risk factor for VTE recurrence.

KW - Clotting activation

KW - Fragment 1 + 2

KW - Oral anticoagulant withdrawal

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=2342439962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342439962&partnerID=8YFLogxK

U2 - 10.1097/00001721-200404000-00004

DO - 10.1097/00001721-200404000-00004

M3 - Article

C2 - 15060417

AN - SCOPUS:2342439962

VL - 15

SP - 221

EP - 225

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 3

ER -